Kornimate/medical-research-clean huggingface dataset:
busulfan and cyclophosphamide instead of total boby irradiation (tbi) and cyclophosphamide for hematological malignancies hematocrit (hct)

Conditions: Acute Leukemias; Chronic Leukemias; Myelodysplastic Syndrome; Juvenile Myelomonocytic Leukemia

Summary: long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (tbi), which are most marked in children radiated at a young age. growth failure, decline in cognitive function, and endocrine abnormalities have all been described. good outcomes can be achieved with alkylating agents only as a preparative regimen. this plan will use a combination of busulfan and cyclophosphamide (bu/cy) with or without antithymocyte globulin (atg) to reduce the late toxicities of therapy that includes tbi.


Eligibility criteria:
inclusion criteria: * suitable cord blood from matched unrelated or related donor. * cardiac (echo/ekg): shortening fraction ≥ 27% * electrolytes within normal cchmc limits. * pulmonary function tests: dlco ≥ 50% * renal: creatinine clearance/gfr ≥ 60 ml/minute/1.73m2 * lumbar puncture: no leukemic infiltrate. * cbc: anc ≥ 1000ml and unsupported platelet count of ≥ 50,000/ml * documented hsv and cmv titers, hepatitis b surface antigen, hepatitis c by serology, hiv by serology: all negative. * hepatic transaminases \< 2.5x normal; total bilirubin \< 2 mg/dl patients who do not meet above organ function criteria (liver, cardiac, renal), due to the presence of a tumor compromising these organs, may have exception made for these criteria and remain eligible for treatment plan after consultation with program director of blood and marrow transplant exclusion criteria: * patients with neoplastic or non-neoplastic disease of any major organ system that would compromise their ability to withstand the pre-transplant conditioning regimen. * patients with uncontrolled (culture or biopsy positive) infections requiring intravenous antivirals, antibiotics, or antifungals. patients on prolonged antifungal therapy with a history of fungal infection should be considered for a non-myeloablative protocol. * patients who are pregnant or lactating. patients of childbearing potential must practice an effective method of birth control while participating on this treatment plan. * hiv seropositive patients

Keywords: stem-cells transplantation busulfex cyclophosphamide total-body-ittadiation
comparison of anthropometric parameters and cardiometabolic risk factors among subjects with overweight and obesity

Conditions: Obesity

Summary: the study was aimed at comparing four different anthropometric parameters to cardiometabolic risk factors in overweight and obese subjects (body mass index (bmi)≥25)

the present study was focused to compare the level of statistical association among four different anthropometric parameters, body mass index (bmi), waist circumference (wc), waist to height ratio (whtr) and neck circumference (nc) and the cardiovascular (cv) risk factors most commonly evaluated in the clinical practice such as systolic and diastolic blood pressure, and fasting glucose, lipid (triglycerides, total, high-density lipoprotein (hdl) and low-density lipoprotein (ldl) cholesterol), insulin, homeostatic model assessment for insulin resistance (homa-ir), uric acid, 25-hydroxyvitamin d (25(oh)d), c-reactive protein (crp), white blood cells and platelet number in a population of 1214 apparently healthy subjects with overweight and obesity subjects

Eligibility criteria:
inclusion criteria: * overweight or obesity (bmi\> 25 kg/m2) exclusion criteria: * any kind of drug * hypertension * endocrine diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), * chronic inflammatory diseases * renal failure * liver failure * angina pectoris * myocardial infarction and heart failure * genetic heart diseases * thrombocytopenias
short and long time effects of iastm and myofascial release techniques in chronic neck pain

Conditions: Chronic Neck Pain

Summary: the aim of this study is to determine whether eyydm and myofascial applications have short and long-term effects on pain and disability in individuals diagnosed with chronic neck pain.

participants will be randomly assigned to iastm, myofascial release and control groups. in addition to conventional treatment, iastm and myofascial release groups will be treated twice a week for 4 weeks. conventional treatment will be applied to the control group for 4 weeks.

Eligibility criteria:
inclusion criteria: * having a diagnosis of chronic neck pain, * to have given at least 3 values to the pain with the numerical pain scale * having bilateral muscle spasms in the cervical region exclusion criteria: * those who are taking any analgesic medication, * those with acute injury or infection, * those with open wounds, * osteoporosis, * fracture, * hematoma, * those with acute cardiac, liver and kidney problems, * those with connective tissue disease, * rheumatoid arthritis, osteoarthritis, * cancer, * those with circulation problems, * those with peripheral vascular disease, * epilepsy, * history of surgery in the cervical region

Keywords: chronic neck pain disability pain
fes and upper limb loading exercises outcome comparison on hand function in spinal cord injury patients

Conditions: Spinal Cord Injuries

Summary: this study is conducted to assess the effectiveness of functional electrical stimulation vs limb loading exercises on hand grip strength,dexterity and function in patients with subacute cervical spinal cord injury.

spinal cord injury (sci) is based on the concept that rehabilitative training recruits neuronal systems spinal cord injury that remain intact after the injury to take over the impaired function.working in the field of rehabilitation of the spinal cord injured, presents many challenges. every patient presents a new and specific challenge. the tetraplegics more so than the paraplegics as the result of loss of active function of their upper extremities in addition to loss of function in the trunk and lower extremities. this study will be conducted to assess the effects of functional electrical stimulation versus limb loading exercises on hand grip strength,dexterity and function in patients with subacute spinal cord injury. trength,dexterity and function in patients with subacute spinal cord injury. the study will be randomized clinical trial. participants will be randomly allocated in to two groups each group will have ten participants.. this study will be conducted in two hospitals in punjab pakistan. the group a will receive functional electrical stimulation .the group b will receive upper limb loading exercises .both groups will be given 30-45 min session 5 days per week for 8 weeks. the outcomes will be measured before and after giving treatment by using modified action research arm test (arat),hand held dynamometry , nine-hole peg test (9hpt). the results will be calculated by using spss 23 version . statistical tests will be applied according to the normality of the data either it will be parametric or non-parametric.

Eligibility criteria:
inclusion criteria: * patients with incomplete sci at neurological level c5-t1 in subacute stage. * medically stable * able to tolerate the functional electrical stimulation without sustained autonomic dysreflexia * a score greater than 16 in mini-mental test exclusion criteria: * patients taking long term steroids * patient having pre-existing injury on upper limb or hand * patients have had previous participation in experimental trial for spinal cord injury * patients using currently cardioactive medications * individuals who has had tendon transfers, implanted devices bladder stimulation, chronic intrathecal infusions * individuals with bleeding disorders. * amputation of any digit on target hand

Keywords: dexterity,functional electrical stimulation,hand function
follow-up to welcome study c87042 [nct00308581] examining certolizumab pegol (cdp870) in subjects with crohn's disease

Conditions: Crohn's Disease

Summary: the study will continue to assess the safety of certolizumab pegol (cdp870) as well as examine the evolution of long term efficacy in crohn's disease patients who completed study c87042 \[nct00308581\]. it will also assess the effect of subcutaneous cdp870 400 mg on direct cost parameters.


Eligibility criteria:
inclusion criteria: * patients having completed study c87042 \[nct00308581\] (previously treated with infliximab) exclusion criteria: * subject withdraw from c87042 \[nct00308581\] study * subject who received treatment other than certolizumab pegol and other than medications permitted in c87042 \[nct00308581\] study * subjects from countries where certolizumab pegol is authorized in crohn's disease treatment * female patients of childbearing age who are not practicing (in the investigator's opinion) effective birth control. all female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration

Keywords: crohn's disease certolizumab pegol cdp870 cimzia
tcr-redirected t cell treatment in patients with recurrent hbv-related hepatocellular carcinoma post liver transplantation

Conditions: Recurrent Hepatocellular Carcinoma

Summary: this is a single-arm and open-label study to assess the safety, tolerability and primary efficacy of the hbv specific t cell receptor (hbv/tcr) redirected t cell in patients with recurrent hepatitis b virus (hbv) related hepatocellular carcinoma post liver transplantation.


Eligibility criteria:
inclusion criteria: 1. diagnosis as hepatocellular carcinoma (hcc). 2. recurrent locally advanced and/or metastatic hepatocellular carcinoma (hcc) post liver transplantation. 3. seropositive for hepatitis b surface antigen, or presence of hbv dna or hbv rna. 4. hla profile matching with hla-class i restriction element of the available t cell receptors. 5. ecog performance status ≤ 2. 6. laboratory criteria: 1. liver function: alt and ast ≤ 5 of upper limit of normal (uln), tbil ≤ 3 x uln. 2. neutrophil cell number ≥1.5×10\^9/l. 3. platelet count ≥100×10\^9/l. 7. ability to provide informed consent. 8. willing and able to comply with all study procedures. exclusion criteria: 1. second primary malignancy that is clinically detectable at the time of consideration for study enrolment. 2. likelihood to require steroid treatment during the period of the clinical trial. 3. lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples. 4. any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. 5. administration of any other cell therapy, including nk, cik, dc, ctl, car- t, stem cells or combined therapy of the kind within 28 days prior to start of treatment. 6. any condition that is unstable or which could jeopardise the safety of the patient and his/her compliance in the study.
improvement of medical quality and outcomes through intelligent management and decision system of cerebrovascular diseases based on hospital information system

Conditions: Cerebrovascular Disease

Summary: this study applied a cerebrovascular disease organizational management and decision system based on hospital information system, aiming to verify the effect of intervention and management after stroke on improving the functional outcomes of acute ischemic cerebrovascular disease through a cluster randomized controlled study.

stroke is a major cerebrovascular disease that causing high morbidity, disability and mortality. management of the acute phase of stroke is critical to functional outcomes. our study aims to verify an intervention method based on hospital information management decision system for the prevention and management of post-stroke treatment in acute stroke patients and improve long-term functional prognosis. this study was a multicenter, open-label, parallel, cohort randomized controlled study, recruiting acute ischemic stroke patients with a post-onset national institutes of health stroke scale (nihss) score of ≥ 2 (limb score ≥1) within 7 days from onset of symptoms. this study will recruit a total of 3540 patients in 30 secondary hospitals. patients in the intervention group will receive the organizational management based clinical decision support system recommended by the guidelines and conduct intervention management for patients with acute ischemic stroke. all patients in control group were treated with conventional diagnosis and treatment. the primary endpoint event was unfavorable functional outcome 3 months after onset. secondary outcomes were in-hospital complications (including pneumonia, deep vein thrombosis), unfavorable functional outcomes at 6 and 12 months of onset (modified rankin score (mrs) score 2-5), recurrent stroke at 3, 6, and 12 months, new vascular events (including ischemic stroke, hemorrhagic stroke, myocardial infarction or vascular death) and all-cause death.

Eligibility criteria:
inclusion criteria: * age ≥ 18. * diagnosed with ischemic stroke confirmed by magnetic resonance imaging (mri) or brain computed tomography (ct). * within 7 days from onset of symptoms. * with a nihss score of ≥2 at admission (limb score ≥1). * with a prestroke mrs score of 0-1. * admission from the emergency department or outpatient service. * voluntary informed consent. exclusion criteria: * diagnosis of other cerebrovascular diseases (cerebral hemorrhage, subarachnoid hemorrhage, cerebral venous sinus thrombosis, etc.). * diagnosis of non-cerebrovascular disease (central nervous system infection, epilepsy, metabolic encephalopathy, etc.). * ischemic stroke with negative diffusion weighted imaging (dwi). * being tested for interventions such as drugs or instruments. * pregnancy or 6 weeks postpartum. * with a life expectancy of less than 3 months or who were unable to complete the study follow-up for other reasons.

Keywords: ischemic stroke medical quality clinical complication clinical decision support system electronic health record artificial intelligence
comparison of self- and balloon-expandable valves in patients with ascending aortic dilation undergoing transcatheter aortic valve replacement: the aad-choice

Conditions: Aortic Stenosis; Ascending Aortic Dilatation

Summary: this study aimed at comparing the performance of self-expandable valves versus balloon-expandable valves in patients with ascending aortic dilation undergoing transcatheter aortic valve replacement.

ascending aortic (aa) dilation is a common feature in patients with aortic stenosis (as), especially in those with bicuspid aortic valve (bav). for patients undergoing surgical aortic valve replacement (savr), current guidelines recommend concomitant aortic repair or replacement if the diameter of aa exceeds 45mm to avoid aortic dissection or rupture. transcatheter aortic valve replacement (tavr) has profoundly changed the clinical management of as patients who cannot tolerate savr. for patients who are candidates for tavr, simultaneous repair of a dilated aa can be technically difficult. the safety and feasibility of the procedure and the fate of aa after the procedure in these patients remain unclear. moreover, there are limited data comparing the performance of self-expandable valves versus balloon-expandable valves in these patients. the aim of the present study is to evaluate the impact of type of transcatheter heart valves on intra-procedural device success and post-procedural aa progression in patients with dilated aa (≥45mm) undergoing tavr.

Eligibility criteria:
inclusion criteria: * severe aortic stenosis; * transfemoral access; * preoperative aortic ct suggesting maximum ascending aortic diameter ≥45mm and \<55mm; * anticipated life expectancy \>1 year; * age ≥ 65 years. exclusion criteria: * dominant aortic regurgitation,; * a history of savr or tavr; * a history of aortic surgery; * emergent tavr.

Keywords: transcatheter aortic valve replacement self-expandable valve balloon-expandable valve
registry for treatment of upper urinary tract tumours

Conditions: Upper Urinary Tract Tumours

Summary: the aim of this registry is to evaluate the incidence, indications and outcomes of patients presenting with utuc in relation to the different treatment modalities used.

this is an observational international multi-center study in which data on consecutive patients with uut tumours are collected. centers from every continent may apply for participation in this registry. data will be collected from consecutive patients over a five year period. patients' data at baseline visit, at one year, three years and five years after inclusion in the registry will be recorded, as well as data on intra- and postoperative complications, recurrence and survival in the whole study period. data from all participating centers will be collected through electronic case report forms (ecrfs), with use of an online data management system (dms), which is located and maintained at the croes office.

Eligibility criteria:
inclusion criteria: * is presenting with a suspected primary utuc (any stage) * is scheduled for treatment of uut tumour * has signed informed consent exclusion criteria: * no specific exclusion criteria are defined.
shoulder kinematics and acute ultrasonographic changes in manual wheelchair users with spinal cord injury

Conditions: Traumatic Spinal Cord Injury

Summary: people who lose function of the lower limb due to spinal cord injury (sci) need to use their arms for activities of daily life especially during weight-bearing tasks, such as transfers, and manual wheelchair (mwc) propulsion in order to maintain mobility. persistent use of the upper limbs constitutes biomechanical difficulties, especially in the shoulder joint. the most commonly affected area in the shoulder is supraspinatus and biceps tendon. four different stoke patterns have been classified in mwc users. distinct amounts of force may be applied to the shoulder joint during propulsion with different stroke patterns and this can affect the shoulder tendons in different rates. in this study, investigators aimed to evaluate and compare the acute sonographic changes in supraspinatus and biceps tendons after a wheelchair propelling test in mwc users with sci with different stroke patterns. also, it is intended to determine the risk factors related to the stroke patterns that may be associated with these sonographic changes.

fourty male mwc users with sci were will be divided into 4 groups according to their stroke patterns (arcing, semicirculer, single loop, and double loop). participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. wheelchair propelling videos will be recorded during the test. shoulder kinematics will be analyzed using kinovea motion analysis software and stoke pattern will be confirmed. ultrasonographic assesment of participants' nondominant shoulder will be performed before and after testing procedure.

Eligibility criteria:
inclusion criteria: * people with traumatic spinal cord injury * age between 18 to 65 years, * neurologic injury level at t2 or below, with ais grade a or b, * time since injury at least 6 months, * using manual wheelchair as their primary mobility tools exclusion criteria: * fractures in nondominant upper limb at any time, * shoulder surgery within the past 5 years or corticosteroid injections within the past 3 months to the nondominant shoulder, * upper limb pain that restricts propulsion of a manual wheelchair, * a history of cardiopulmonary problems and degenerative joint diseases

Keywords: spinal cord injury stroke pattern ultrasonography
plaque removal versus open bypass surgery for critical limb ischemia

Conditions: Peripheral Vascular Diseases

Summary: to compare the outcome of bypass surgery and plaque excision for treatment of critical limb ischemia in the lower limbs


Eligibility criteria:
inclusion criteria: * ischemic rest pain for more than 2 weeks or ulceration or gangrene of the foot or toes (rutherford becker category 4, 5 or 6) * willing and able, as evaluated by the pi, to provide informed consent * willing to undergo up to 5 years of clinical follow up visits as scheduled * angiographic pattern of infrainguinal disease that can be reasonably managed either by surgery or plaque excision in the first instance * reconstitution of at least one patent target tibial segment below the knee which provides run-off to the foot * the patient must be \>18 years of age * target lesion(s) is located at or below the level of the superficial femoral artery * target lesion(s) is \>50% stenosed by quantitative vascular angiography * ability to take at least one of the following types of medications: anti- platelet or anti-thrombotic therapy exclusion criteria: * patient has cardiac or cardiovascular comorbidities that would make surgery inappropriate * patient has terminal or stage 4 cancer * patient has extensive gangrene that requires both a below-the-knee amputation and a revascularization procedure * previous stent in the target lesion * active infection at planned incision site * the patient is a pregnant woman * the patient has significant suprainguinal or common femoral disease that can not be treated either prior to or during the index procedure * target lesion is a chronic total occlusion (cto) that is greater than 15cm in length and has severe, continuous calcification

Keywords: cli critical limb ischemia pad peripheral arterial disease artherosclerosis leg pain cardiovascular artherectomy bypass peripheral bypass proof
incidence and associated factors of persistent postoperative incision scar pain following c/s in mulago hospital

Conditions: Chronic Pain

Summary: prospective cohort study of women who underwent caesarean section in mulago hospital. followed up for 2 months and assessed for development of persistent post operative pain at the incision site and its effect on quality of life. incidence of persistent postoperative pain and associated factors determined.

prospective cohort study of 277 women who underwent caesarean section in mulago hospital. demographic, medical history, intraoperative, postoperative details, and perioperative levels of pain collected. followed up by telephone interviews for 2 months and assessed for development of persistent post operative pain at the incision site and its effect on quality of life. incidence of persistent postoperative pain and associated factors determined.

Eligibility criteria:
inclusion criteria: - asa i, ii, and iii. * patient who has given informed consent. exclusion criteria: * patients who have no telephone contact